Selected research
Industry Research
Celiac Drugs Industry Research Report 2026
Market perspective
The global Celiac Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Celiac Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Celiac Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Celiac Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Celiac Drugs include Johnson & Johnson, Novartis, Merck, Biogen, Bayer, Amgen, LFB Group, Kedrion Biopharma and Innovate Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Celiac Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Celiac Drugs Market by Company
Johnson & Johnson
Novartis
Merck
Biogen
Bayer
Amgen
LFB Group
Kedrion Biopharma
Innovate Biopharmaceuticals
ImmusanT
Immunomedics
ImmunogenX
F Hoffmann-La Roche
Celimmune
Celgene
Bristol-Myers Squibb
Biotest
BioLineRx
Anthera Pharmaceuticals
ADMA Biologics
Celiac Drugs Segment by Type
First Line Of Treatment
Second Line Of Treatment
Celiac Drugs Segment by Application
Women
Men
Children
Celiac Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Celiac Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Celiac Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Celiac Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Celiac Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Celiac Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Celiac Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Of Treatment
- Second Line Of Treatment
Applications
- Women
- Men
- Children
Companies covered
- Johnson & Johnson
- Novartis
- Merck
- Biogen
- Bayer
- Amgen
- LFB Group
- Kedrion Biopharma
- Innovate Biopharmaceuticals
- ImmusanT
- Immunomedics
- ImmunogenX
- F Hoffmann-La Roche
- Celimmune
- Celgene
- Bristol-Myers Squibb
- Biotest
- BioLineRx
- Anthera Pharmaceuticals
- ADMA Biologics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Celiac Drugs Market Size (2021-2032)
- 2.2.2 Global Celiac Drugs Sales (2021-2032)
- 2.2.3 Global Celiac Drugs Market Average Price (2021-2032)
- 2.3 Celiac Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 First Line Of Treatment
- 2.3.3 Second Line Of Treatment
- 2.4 Celiac Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Women
- 2.4.3 Men
- 2.4.4 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Celiac Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Celiac Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Celiac Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Celiac Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Celiac Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Celiac Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Celiac Drugs, Product Type & Application
- 3.8 Global Manufacturers of Celiac Drugs, Established Date
- 3.9 Global Celiac Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Celiac Drugs Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Celiac Drugs Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Celiac Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Biogen
- 4.4.1 Biogen Company Information
- 4.4.2 Biogen Business Overview
- 4.4.3 Biogen Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Biogen Celiac Drugs Product Portfolio
- 4.4.5 Biogen Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Celiac Drugs Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Celiac Drugs Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 LFB Group
- 4.7.1 LFB Group Company Information
- 4.7.2 LFB Group Business Overview
- 4.7.3 LFB Group Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 LFB Group Celiac Drugs Product Portfolio
- 4.7.5 LFB Group Recent Developments
- 4.8 Kedrion Biopharma
- 4.8.1 Kedrion Biopharma Company Information
- 4.8.2 Kedrion Biopharma Business Overview
- 4.8.3 Kedrion Biopharma Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Kedrion Biopharma Celiac Drugs Product Portfolio
- 4.8.5 Kedrion Biopharma Recent Developments
- 4.9 Innovate Biopharmaceuticals
- 4.9.1 Innovate Biopharmaceuticals Company Information
- 4.9.2 Innovate Biopharmaceuticals Business Overview
- 4.9.3 Innovate Biopharmaceuticals Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Innovate Biopharmaceuticals Celiac Drugs Product Portfolio
- 4.9.5 Innovate Biopharmaceuticals Recent Developments
- 4.10 ImmusanT
- 4.10.1 ImmusanT Company Information
- 4.10.2 ImmusanT Business Overview
- 4.10.3 ImmusanT Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 ImmusanT Celiac Drugs Product Portfolio
- 4.10.5 ImmusanT Recent Developments
- 4.11 Immunomedics
- 4.11.1 Immunomedics Company Information
- 4.11.2 Immunomedics Business Overview
- 4.11.3 Immunomedics Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Immunomedics Celiac Drugs Product Portfolio
- 4.11.5 Immunomedics Recent Developments
- 4.12 ImmunogenX
- 4.12.1 ImmunogenX Company Information
- 4.12.2 ImmunogenX Business Overview
- 4.12.3 ImmunogenX Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 ImmunogenX Celiac Drugs Product Portfolio
- 4.12.5 ImmunogenX Recent Developments
- 4.13 F Hoffmann-La Roche
- 4.13.1 F Hoffmann-La Roche Company Information
- 4.13.2 F Hoffmann-La Roche Business Overview
- 4.13.3 F Hoffmann-La Roche Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 F Hoffmann-La Roche Celiac Drugs Product Portfolio
- 4.13.5 F Hoffmann-La Roche Recent Developments
- 4.14 Celimmune
- 4.14.1 Celimmune Company Information
- 4.14.2 Celimmune Business Overview
- 4.14.3 Celimmune Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Celimmune Celiac Drugs Product Portfolio
- 4.14.5 Celimmune Recent Developments
- 4.15 Celgene
- 4.15.1 Celgene Company Information
- 4.15.2 Celgene Business Overview
- 4.15.3 Celgene Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Celgene Celiac Drugs Product Portfolio
- 4.15.5 Celgene Recent Developments
- 4.16 Bristol-Myers Squibb
- 4.16.1 Bristol-Myers Squibb Company Information
- 4.16.2 Bristol-Myers Squibb Business Overview
- 4.16.3 Bristol-Myers Squibb Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Bristol-Myers Squibb Celiac Drugs Product Portfolio
- 4.16.5 Bristol-Myers Squibb Recent Developments
- 4.17 Biotest
- 4.17.1 Biotest Company Information
- 4.17.2 Biotest Business Overview
- 4.17.3 Biotest Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Biotest Celiac Drugs Product Portfolio
- 4.17.5 Biotest Recent Developments
- 4.18 BioLineRx
- 4.18.1 BioLineRx Company Information
- 4.18.2 BioLineRx Business Overview
- 4.18.3 BioLineRx Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 BioLineRx Celiac Drugs Product Portfolio
- 4.18.5 BioLineRx Recent Developments
- 4.19 Anthera Pharmaceuticals
- 4.19.1 Anthera Pharmaceuticals Company Information
- 4.19.2 Anthera Pharmaceuticals Business Overview
- 4.19.3 Anthera Pharmaceuticals Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Anthera Pharmaceuticals Celiac Drugs Product Portfolio
- 4.19.5 Anthera Pharmaceuticals Recent Developments
- 4.20 ADMA Biologics
- 4.20.1 ADMA Biologics Company Information
- 4.20.2 ADMA Biologics Business Overview
- 4.20.3 ADMA Biologics Celiac Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 ADMA Biologics Celiac Drugs Product Portfolio
- 4.20.5 ADMA Biologics Recent Developments
5 Global Celiac Drugs Market Scenario by Region
- 5.1 Global Celiac Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Celiac Drugs Sales by Region: 2021-2032
- 5.2.1 Global Celiac Drugs Sales by Region: 2021-2026
- 5.2.2 Global Celiac Drugs Sales by Region: 2027-2032
- 5.3 Global Celiac Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Celiac Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Celiac Drugs Revenue by Region: 2027-2032
- 5.4 North America Celiac Drugs Market Facts & Figures by Country
- 5.4.1 North America Celiac Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Celiac Drugs Sales by Country (2021-2032)
- 5.4.3 North America Celiac Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Celiac Drugs Market Facts & Figures by Country
- 5.5.1 Europe Celiac Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Celiac Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Celiac Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Celiac Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Celiac Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Celiac Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Celiac Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Celiac Drugs Market Facts & Figures by Country
- 5.7.1 South America Celiac Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Celiac Drugs Sales by Country (2021-2032)
- 5.7.3 South America Celiac Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Celiac Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Celiac Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Celiac Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Celiac Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Celiac Drugs Sales by Type (2021-2032)
- 6.1.1 Global Celiac Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Celiac Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Celiac Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Celiac Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Celiac Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Celiac Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Celiac Drugs Sales by Application (2021-2032)
- 7.1.1 Global Celiac Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Celiac Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Celiac Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Celiac Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Celiac Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Celiac Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Celiac Drugs Value Chain Analysis
- 8.1.1 Celiac Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Celiac Drugs Production Mode & Process
- 8.2 Celiac Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Celiac Drugs Distributors
- 8.2.3 Celiac Drugs Customers
9 Global Celiac Drugs Analyzing Market Dynamics
- 9.1 Celiac Drugs Industry Trends
- 9.2 Celiac Drugs Industry Drivers
- 9.3 Celiac Drugs Industry Opportunities and Challenges
- 9.4 Celiac Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst